NDAORALTABLET
Approved
Dec 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
ADVIL PM (advil pm) by GSK is cyclooxygenase inhibitors [moa]. First approved in 2005.
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ADVIL PM is an over-the-counter oral tablet combining ibuprofen (NSAID) with a sleep aid for nighttime pain relief. It works via cyclooxygenase inhibition to reduce inflammation and pain while promoting sleep. The product targets consumers seeking combined pain management and sleep support.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); expect focused retention efforts and potential team restructuring as patent protection weakens.
Mechanism of Action
Cyclooxygenase Inhibitors
Pharmacologic Class:
Nonsteroidal Anti-inflammatory Drug
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ADVIL PM offers limited career growth opportunities due to mature lifecycle and approaching LOE; roles are primarily defensive and focused on market retention rather than innovation or expansion. Professionals seeking dynamic growth should consider this a portfolio stabilization assignment rather than a high-impact career accelerator.
Brand Manager
Worked on ADVIL PM at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.